Healthcare Industry News: radiopharmaceuticals
News Release - June 9, 2016
NuView Life Sciences Appoints Joel R. Timberlake as President of US RadiopharmaceuticalsPARK CITY, Utah, June 9, 2016 -- (Healthcare Sales & Marketing Network) -- NuView Life Sciences today announced that Joel R. Timberlake has been appointed president of US radiopharmaceuticals (USR), the company's manufacturing and distribution subsidiary of medical isotopes and radiopharmaceuticals.
As president of US radiopharmaceuticals, Mr. Timberlake will focus on executing the Company's business plan to expand the facility and develop relationships with supply-chain companies as a full service provider of radiopharmaceuticals and medical isotopes.
"Joel is an excellent fit for our company," said NuView Life Sciences CEO Paul Crowe. "Having worked with him through our on-going relationship with Otsuka Pharmaceuticals, he has a deep understanding of the sector, making him uniquely qualified for the position. Joel will spearhead the USR team's efforts to expand the USR facility for manufacturing and distribution of medical isotopes, radiopharmaceutical products, Tc-99m generators and the platform technology NV-VPAC1 for in-vivo and in-vitro diagnostics."
Mr. Timberlake has extensive experience in managing manufacturing, sales and operations on a global scale. Most recently, he was COO at Otsuka Pharmaceuticals' Interpharma Praha, a custom development and manufacturing company that partners with clients in Europe, Japan and North America to assist them in the development of active pharmaceutical ingredients, neutraceuticals and drug products. Prior to that Mr. Timberlake held a variety of senior management roles at Metrogroup Marketing Services and Tyco Healthcare's Mallinckrodt Imaging Division as well as the Kendall Company. Throughout his career, Mr. Timberlake led the development and implementation of manufacturing strategies, directed operations, marketing services, customer service, distribution, corporate procurement, planning, and operations IT.
"NuView Life Sciences development of a new biomarker for positron emission tomography (PET) and the reopening of the radiopharmaceutical manufacturing facility with a robust product portfolio, is an exciting opportunity," said Joel Timberlake. "I'm looking forward to working with the team at NuView to advance the company's vision to become an industry leader."
About NuView Life Sciences
NuView is a privately held, Utah-based, biotechnology company. The company developed a new cancer biomarker platform with high affinity to bind only to the surface of cancer cells. The new biomarker has potential utilization for in-vivo diagnostic imaging, in-vivo therapy delivery and in-vitro as a liquid biopsy procedure binding to shed cancer cells found in bio-fluids. For additional information about NuView Life Sciences, Inc., visit http://www.nuviewinfo.com.
About US radiopharmaceuticals
US radiopharmaceuticals is a privately held subsidiary of NuView Life Sciences. The company has 25 acres with 85,000-square-feet of FDA-registered, cGMP medical isotope manufacturing and distribution facilities located in Denton, Texas. USR has a portfolio of six FDA-registered products and will be expanding the manufacturing facility for Tc-99m generators. For additional information about US radiopharmaceuticals, visit http://usradiopharma.us/.
Source: NuView Life Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.